| Name | Title | Contact Details |
|---|
Clementia is a biopharmaceutical company that is focused on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease. Our lead program is palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
With offices in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies. The Company`s first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company is preparing for clinical trials in the U.S. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.
Cadence Neuroscience is developing a next generation implantable device therapy for epilepsy. The therapy, pioneered by researchers at Mayo Clinic over the past decade, uses advanced methods to provide individualized treatment for each patient. Our core technology includes a specialized neuromodulation platform that enables these methods. Cadence is currently engaged in the engineering and testing of the platform, and preparing for additional clinical evaluations.
Nura Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hawaii Biotech is a Aiea, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.